Last Updated : April 8, 2020
Details
FilesGeneric Name:
Trifluridine-Tipiracil
Project Status:
Complete
Therapeutic Area:
Gastric Cancer
Manufacturer:
Taiho Pharma Canada, Inc.
Brand Name:
Lonsurf
Project Line:
Reimbursement Review
Project Number:
PC0197-000
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Strength:
15 mg / 6.14 mg and 20 mg / 8.19 mg
Tumour Type:
Gastrointestinal
Indications:
Gastric Cancer
Funding Request:
For the treatment of adult patients with metastatic gastric cancer or adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior lines of chemotherapy including a fluoropyrimidine, a platinum, and either a taxane or irinotecan and if appropriate with HER2/neu-targeted therapy
Pre Noc Submission:
Yes
Sponsor:
Taiho Pharma Canada, Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : April 8, 2020